Monday, December 18, 2006

Genomic Health Announces Multiple New Findings On Oncotype DX(TM) Based On Evaluation Of More Than 20,000 Tumor Samples

Genomic Health, Inc. (Nasdaq: GHDX) today announced the results of several studies looking at the roles and relationships of genes measured by the company's Oncotype DX breast cancer assay, including an analysis of more than 10,000 node-negative tumors indicating that all 21 genes impact the assessment of an individual woman's tumor. This research was presented at the 29th Annual San Antonio Breast Cancer Symposium.Oncotype DX measures the expression of 16 cancer-related genes plus 5 reference genes of an individual tumor to generate a "Recurrence Score" to quantify risk of recurrence and likelihood of response to chemotherapy. To assess the degree to which components of this multi-gene assay influence the Recurrence Score, researchers measured expression of the 16 individual cancer genes relative to reference genes in 10,618 tumor specimens on a scale of 0 to 15, where a one-unit increment is associated with a twofold change in expression. Results suggest that every cancer gene used in the Oncotype DX 21-gene panel impacts the Recurrence Score due to the potentially large variation in quantitative expression for each gene in different patients. The study found this result even though expression of certain genes and gene families; including ER, HER2 and a group of five genes linked to proliferation, have the largest coefficients used in calculating the Recurrence Score. --Click the title of this post to read the full article from its source--

Labels: , , ,

/* WebRing Code */